Acebrophylline-induced generalized fixed drug eruption confirmed by an oral provocation test.
10.4168/aard.2017.5.5.298
- Author:
Su Jin JEONG
1
;
Heon SA-KONG
;
Dong Hee PARK
;
Sung Geun LEE
;
So Young JUNG
;
Chan Sun PARK
Author Information
1. Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. chansun@paik.ac.kr
- Publication Type:Case Report
- Keywords:
Acebrophylline;
Drug eruptions;
Patch tests
- MeSH:
Adult;
Biopsy;
Clarithromycin;
Dermis;
Diagnosis;
Drug Eruptions*;
Eating;
Epidermis;
Female;
Humans;
Hyperpigmentation;
Keratinocytes;
Patch Tests;
Pseudoephedrine;
Recurrence;
Skin
- From:Allergy, Asthma & Respiratory Disease
2017;5(5):298-301
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The diagnosis of fixed drug eruption is straightforward because of characteristic findings, including recurrence of similar lesions at the same site and healing with residual hyperpigmentation. However, generalized or multiple fixed drug eruption, a rare variant form, can be a diagnostic challenge. Acebrophylline is a widely prescribed oral bronchodilator with mucosecretolyic and anti-inflammatory activity and is known to be relatively safe. A 34-year-old woman presented with recurrent numerous erythematous patches after ingestion of cold medications containing clarithromycin, loxoprofen, acebrophylline, and pseudoephedrine. Skin biopsy results showed vacuolar degeneration of the basal cell layer, scattered necrotic keratinocytes in the epidermis, and perivascular lymphohistiocytic infiltration in the upper dermis. A patch test showed negative results. However, in an oral challenge with acebrophylline 3 hours later, lesions reappeared at the same sites. To the best of our knowledge, this is the first case report of acebrophylline-induced generalized fixed drug eruption.
